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Summary
HMGA2 gene amplification and overexpression in human prolactinomas and the development of pituitary adenomas in
HMGA2 transgenic mice showed that HMGA2 plays a crucial role in pituitary tumorigenesis. We have explored the pRB/
E2F1 pathway to investigate the mechanism by which HMGA2 acts. Here we show that HMGA2 interacts with pRB and in-
duces E2F1 activity in mouse pituitary adenomas by displacing HDAC1 from the pRB/E2F1 complex—a process that results
in E2F1 acetylation. We found that loss of E2F1 function (obtained bymatingHMGA2 and E2F12/2mice) suppressed pituitary
tumorigenesis in HMGA2 mice. Thus, HMGA2-mediated E2F1 activation is a crucial event in the onset of these tumors in
transgenic mice and probably also in human prolactinomas.Introduction
High mobility group A (HMGA) proteins are nonhistone nuclear
compounds known as architectural transcriptional factors be-
cause they mediate the assembly of multiprotein complexes in-
volved in gene transcription. In fact, by interacting with theminor
groove of many AT-rich promoters and enhancers, HMGA pro-
teins do not per se exert transcriptional activity, but organize
chromatin into the structure required by the transcription ma-
chinery to allow gene transcription. There are four HMGA pro-
teins: HMGA1a, HMGA1b, HMGA1c, and HMGA2. The first
three are encoded by the gene HMGA1, whereas HMGA2 is en-
coded by HMGA2. HMGA2 is almost ubiquitously expressed at
high levels during embryogenesis, whereas in adult tissues it
occurs only in CD34-positive hematopoietic stem cells, uterine
myoblasts, testicular cells, and proliferating preadipocytes. Its
function is critical for growth and adipocytic cell differentiation.
In fact, its impairment results in pygmymicewith greatly reduced
fat tissue, whereas its activation by truncation leads to giantCANCER CELL 9, 459–471, JUNE 2006 ª2006 ELSEVIER INC. DOI 10.10mice affected by lipomatosis. HMGA2 overexpression was first
demonstrated in rat thyroid transformed cells and experimental
thyroid tumors. Subsequent studies showed that HMGA2 ex-
pression is required for thyroid cell neoplastic transformation
and that HMGA2 expression is correlated with humanmalignant
tumors. HMGA2 rearrangements are frequent in benign tumors
ofmesenchymal origin (reviewed by Fedele et al., 2001).We pre-
viously found that the HMGA2 gene is amplified and overex-
pressed in most human prolactinomas characterized by chro-
mosome 12 trisomy and tetrasomy (Finelli et al., 2002) and that
transgenic mice expressing high levels of theHMGA2 transgene
in all tissues develop pituitary adenomas secreting prolactin and
growth hormone, thereby confirming thatHMGA2 plays a critical
role in human pituitary adenomas (Fedele et al., 2002).
The aim of our study was to investigate the mechanisms by
which HMGA2 leads to the onset of pituitary adenomas in
HMGA2 transgenic mice and probably also in humans.
There are striking phenotypic similarities between the pRB
and HMGA2 animal models. In fact, transgenic miceS I G N I F I C A N C E
Themolecular pathway leading to pituitary tumorigenesis is one of the challenges of endocrine oncology. Here, we describe amech-
anism by which HMGA2 induces pituitary adenomas in mice. This mechanism entails an HMGA2-dependent process that relieves
pRB-mediated repression of E2F1. It is likely that the same mechanism is involved in most of the human prolactinomas in which the
HMGA2 gene is amplified and overexpressed. Elucidation of the mechanism by which HMGA2 induces pituitary adenomas opens
up the possibility of intervening in this mechanism to prevent or halt the onset of these tumors.16/j.ccr.2006.04.024 459
A R T I C L EFigure 1. HMGA2 increases E2F1 DNA binding
activity in pituitary adenomas
A: EMSA with extracts from a pool of pituitary
glands (lanes 1–3) and two pituitary adenomas
(lanes 4–11) of HMGA2 transgenic mice using
an E2F-responsive element sequence (E2FRE) as
a probe. Samples were incubated with E2FRE
(lanes 1, 4, and 8) or were preincubated with
1003CD28 responsive element (CD28RE), which
is a specific competitor for HMGA2 binding
(lanes 3, 6, and 10), with 1003 E2FRE unlabeled
probe (lanes 2–5 and 9), and with specific poly-
clonal anti-HMGA2 antibody (lanes 7 and 11),
before the addition of the probe. Arrows indi-
cate specifc complexes DNA/proteins.
B: EMSA of pituitary extracts of adenomas from
HMGA2 transgenic mice with E2FRE (lanes 1
and 2) or E2FRE mutated in the region rich in AT
bases (AT-mut; lane 3). The samples in lanes 1
and 2 were incubated without (lane 1) or with
anti-E2F1 antibody (lane 2), before the addition
of the probe. His-HMGA2 (lanes 4–5) or GST-
E2F1 (lanes 6–7) recombinant proteins were incu-
bated with E2FRE or AT-mut, as indicated above.overexpressing pRB show a dwarf phenotype because of de-
fective cell proliferation (Bignon et al., 1993) as do HMGA2 null
mice. Conversely, Rb+/2 mice are larger than their littermates
(Jacks et al., 1992), as are transgenic mice carrying an activated
HMGA2 gene (Battista et al., 1999). Moreover, mice carrying
a germline mutation of one Rb allele are highly predisposed to
develop pituitary tumors (Jacks et al., 1992), and this occurs
also in mice with impaired functioning of p27 or p18, both of
which converge on pRB (Franklin et al., 1998).
The finding that loss of E2F1 reduced pituitary tumorigenesis
in Rb knockout mice suggests that loss of pRB induces the on-
set of pituitary tumors by activating E2F1 (Yamasaki et al., 1998).
We therefore investigated the role of the pRB pathway in the
onset of pituitary adenomas in transgenic mice overexpress-
ing HMGA2.
pRB and the related proteins p130 and p107 control cell cycle
progression through their interactions with the E2F family of
transcription factors. E2F1 is known to activate transcription
of a number of genes required for the S phase of the cell cycle.
Transcriptional repression of E2F1 target genes entails recruit-
ment of pRB by E2F1 to the gene promoters. This recruitment
masks the activation domain of E2F1 and prevents its interac-
tion with the general transcriptional machinery. Before cells
enter S phase, pRB is phosphorylated atmultiple sites by cyclin-
dependent kinases. This phosphorylation leads to pRB inactiva-
tion, release of E2F1, and transcriptional activation of its target
genes (reviewed by Seville et al., 2005). Moreover, pRB recruits
class I histone deacetylase proteins that repress transcription by
removing acetyl groups from the histones. Removal of the acetyl
groups facilitates the condensation of nucleosomes into chro-
matin, which in turn blocks access to transcription factors and
leads to gene repression (Magnaghi-Jaulin et al., 1998).
Here we report that HMGA2 binds to pRB and prevents it from
repressing the E2F1-responsive promoters mainly by displacing
HDAC1 from pRB. This results in enhanced acetylation of both
E2F1 and associated histones, which could account for the en-
hanced E2F1 activity observed in HMGA2-induced pituitary ad-
enomas and associated with the HMGA2 overexpression. To
verify the crucial role of enhanced E2F activity in the onset of460pituitary adenomas, we mated transgenic mice overexpressing
HMGA2with E2F1 knockoutmice (Field et al., 1996). The adeno-
matous phenotype was almost totally rescued in the double
mutant mice, which demonstrates that HMGA2-mediated E2F1
activation is a prerequisite for pituitary tumorigenesis.
Results
E2F1 DNA binding activity is increased in pituitary
adenomas of HMGA2 transgenic mice
To investigate whether the pRB/E2F1 pathway is involved in pi-
tuitary tumorigenesis in HMGA2 transgenic mice, we analyzed
E2F DNA binding activity in HMGA2 pituitary adenomas and
normal pituitary glands from control mice by electrophoretic
mobility shift assay (EMSA) using an E2F-responsive element
(E2FRE) as probe. As shown in Figure 1A, E2F1 DNA binding ac-
tivity was dramatically higher in HMGA2 pituitary adenomas
than in pituitary glands from control mice. A specific complex
containing E2F (complex A) was present in normal pituitary
gland (lane 1). Another, faster-migrating complex (complex B)
was associated with pituitary adenomas from HMGA2 mice
(lanes 4 and 8). Competition analyses with specific anti-E2F1
antibodies showed that this band corresponds to the free
E2F1-DNA complex (Figure 1B, lane 2). Band specificity was as-
sessed by adding a 1003molar excess of unlabeled probe (Fig-
ure 1A, lanes 2, 5, and 9). Preincubation with an oligonucleotide
(CD28RE) that specifically binds to HMGA2 (Baldassarre et al.,
2001) prevented the formation of this complex (Figure 1A, lanes
6 and 10). Moreover, an antibody against HMGA2 significantly
reduced the band corresponding to complex B (Figure 1A, lanes
7 and 11). These data show that HMGA2 plays a crucial role in
the formation of complex B.
HMGA2 binds to the E2F1 responsive element
and enhances the binding of E2F1 to DNA
HMGA proteins allow the assembly of multiprotein complexes
by directly binding to the DNA in AT-rich sequences. We used
an E2F consensus oligonucleotide (E2FRE) that has an AT
stretch compatible with HMGA binding in an EMSA assay withCANCER CELL JUNE 2006
A R T I C L Ea recombinant HMGA2 protein. As shown in lane 4 of Figure 1B,
HMGA2was able to bind to the E2F-responsive oligonucleotide,
but not to the same oligonucleotide mutated in the AT-stretch
flanking the E2F-consensus sequence (AT-mut). Interestingly,
the binding of free E2F1 to DNA in pituitary adenomas from
HMGA2 transgenic mice was considerably decreased on the
AT-mut probe (Figure 1B, lane 3). Because the binding of the re-
combinant E2F1 to its consensus DNA was not impaired by the
ATmutation (Figure 1B, lanes 6 and 7), we suggest that the bind-
ing of HMGA2 to its consensus sequence, flanking the E2F
binding site, is crucial for efficient E2F1/DNA binding.
HMGA2 interacts with the pRB protein
Since free E2F1/DNA binding depends essentially on E2F1 re-
lease from pRB, HMGA2 may interfere with the pRB pathway.
To investigate whether HMGA2 interacts with pRB, we coimmu-
noprecipitated protein lysates from twoHMGA2pituitary adeno-
mas and from a pool of pituitary glands from control mice.
Immunoprecipitation of the protein lysates with anti-pRB anti-
bodies resulted in the coimmunoprecipitation of HMGA2 from
pituitary adenomas (Figure 2A, left panels). Western blot analy-
sis showed that pRB was equally expressed in pituitary glands
and adenomas, whereas the HMGA2 protein was expressed
only in HMGA2 pituitary adenomas.
We next verified the HMGA2/pRB interaction in a heterolo-
gous cell system. HEK293 cells were transiently cotransfected
with hemagglutinin (HA)-tagged-HMGA2 and pRB expression
vectors. Protein lysates were immunoprecipitated with anti-
pRB or anti-HA antibodies and immunoblotted with anti-HA or
anti-pRB, respectively (Figure 2A, right panels). Coexpression
of pRB and HMGA2 resulted in coimmunoprecipitation of the
two proteins. Conversely, there was no coimmunoprecipitation
when HEK293 cells were transfected with HA-HMGA2 or pRB
expression vectors alone. Indeed, consistent with the endoge-
nous expression of pRB in HEK293 cells, longer exposure times
resulted in a faint band in HA-HMGA2 transfected cells (data not
shown).
The HMGA2/pRB interaction is direct and involves either
the pocket region or the N terminus of pRB
To determine whether HMGA2 interacts directly with pRB, we
carried out Far-Western analyses in which we probed HMGA2
on pRB immunoprecipitates from cell lysates overexpressing
wild-type and different mutant forms of the pRB protein (Figures
2B and 2C). Interestingly, HMGA2 was found to bind to the pRB
mutant expressing only the pocket region (lane 5) as efficiently
as to the wild-type pRB (lane 1). It did not bind to the naturally
occurring mutant pRBD21 that carries a deletion of exon 21
and encodes a portion of the pocket region (lane 4). pRB mu-
tants 661 and 13S, which carry a point mutation in the pRB
pocket region and amino acid substitutions and insertions in
the C-terminal region, respectively (lanes 2 and 3), did not affect
binding between pRB and HMGA2.
These results are supported by in vitro binding experiments in
which GST-pRB fusion proteins containing various pRB do-
mains (Figure 2B) were incubated with a lysate from cells over-
expressing HMGA2 (Figure 2D). pRB(379-928), which contains
the entire wild-type pocket region of pRB plus the C-terminal re-
gion, was able to bind efficiently to HMGA2 (lane 1). In con-
trast, pRB(379-928)D21, which lacks the region corresponding
to exon 21, only weakly associated with HMGA2 (lane 3).CANCER CELL JUNE 2006pRB(768-928) and pRB(834-928), which carry the C-terminal re-
gion plus a small region of the pocket and the C-terminal region
only, respectively, did not bind to HMGA2 at all (lanes 5 and 6).
Finally, pRB(1-379) and pRB(379-792), carrying the N-terminal
region and the pocket region, respectively, were able to bind ef-
ficiently to HMGA2 (lanes 2 and 4). These results indicate that
HMGA2 binds to pRB in two regions: the N terminus and the
pocket region between amino acids 703 and 737.
The second AT-hook of HMGA2 is required
for interaction with pRB
We next investigated the regions of HMGA2 that are required to
form a complex with pRB. HMGA2 contains three AT-hook do-
mains that are involved in both DNA and protein-protein interac-
tions, and an acidic C-terminal tail preceded by a spacer region
(Figure 2E). We used cell lysates expressing HA-HMGA2 mu-
tants carrying serial deletions at the N and C terminus regions
(Figure 2E) in a pull-down assay with a recombinant GST-pRB
protein (Figure 2F, lanes 1–6). The only mutant that lost the ca-
pacity to bind to pRB was A2(1-44), which contains the N termi-
nus, the first AT-hook, and the region preceding the second AT-
hook. Because all the other mutants, including A2(1-56), which
encodes the same protein portion as mutant A2(1-44) plus the
second AT-hook, were able to bind to pRB as efficiently as the
wild-type HMGA2, we suggest that the second AT-hook domain
of HMGA2 is principally involved in binding to pRB. Tomapmore
precisely the HMGA2 region involved in forming a complex with
pRB, we generated an HMGA2 mutant lacking only the second
AT-hook [A2(D45-56) ] (Figure 2E) and used it in a pull-down assay
with the GST-pRB protein (Figure 2F, lane 7). The A2(D45-56) mu-
tant was less able than wild-type HMGA2 to bind to pRB. This
confirms that the region of HMGA2 coding for the second AT-
hook is principally involved in binding pRB and suggests, how-
ever, that other regions of the HMGA2 protein might also be in-
volved in this binding.
HMGA2 overexpression counteracts pRB-mediated
inhibition of E2F activity and cell proliferation
To define better the role of the pRB/HMGA2 interaction in the
regulation of E2F1 transcriptional activity, we examined the ac-
tivity of two E2F1-responsive promoter genes, i.e., CDC25A and
CDC6, fused to a luciferase reporter gene, in the HEK293 cells
transiently transfected with plasmids expressing the pRB and
HMGA2 proteins. As shown in Figure 3A, pRB repressed
CDC6 and CDC25A promoter activity (3-fold decrease),
whereas HMGA2 increased these activities (up to 3-fold) in
a dose-dependent manner. When pRB was cotransfected with
increasing levels of HMGA2, pRB repression of CDC25A and
CDC6 promoter activity was significantly antagonized. In partic-
ular, 5 mg of transfected HMGA2 vector abolished repression,
and 10 mg of HMGA2 caused a switch from repression to activa-
tion (2.5-fold increase). Similar experiments were carried out in
pRB null Saos-2 cells by transfecting pRB, HMGA2, and mu-
tants A2(1-44) or A2(D45-56), as indicated in Figure 3B. In the
absence of pRB, HMGA2 does not affect E2F target gene
activation, and neither of the mutants antagonized the pRB-
mediated inhibition of the promoter-response activity, which
suggests that HMGA2 binding to pRB is required for this effect.
The results of a colony-forming assay of Saos-2 cells demon-
strate that HMGA2 antagonizes the pRB-mediated inhibition of
cell proliferation (Figure 3C). The expression of transfected461
A R T I C L EFigure 2. HMGA2 interacts with pRB
A: Left panels. Lysates from a pool of pituitary glands of control mice and from the pituitary adenomas shown in Figure 1 were subjected to Western blot anal-
ysis with either anti-pRB or anti-HMGA2 antibodies to verify protein expression. The expression of g-tubulin served to verify equal loading of proteins. The same
lysates were immunoprecipitated with anti-pRB antibody, resolved by SDS-PAGE, and analyzed by Western blot with anti-HMGA2 antibody. Immunoprecip-
itation in the presence of EtBr and with IgG were also performed as control of the specificity of the interaction. Right panels. Whole-cell lysates from HEK293
cells untransfected or transfected with the indicated expression plasmids were immunoprecipitated with anti-pRB (upper panel) or anti-HA (lower panel) an-
tibodies, run on an SDS-PAGE gel, and transferred to nitrocellulose. The blot was probed with anti-HA or anti-pRB antibodies, respectively.
B: Schematic representation of GST-pRB fusion proteins and pRB expressing plasmids used for the analysis.
C: Whole-cell lysates from HEK293 cells transfected with plasmids expressing pRB proteins, as described in (B) were immunoprecipitated with either anti-pRB
polyclonal antibody or preimmune serum. After being washed, samples were run on an SDS-PAGE gel and transferred to nitrocellulose. The blot was probed
with His-HMGA2 in a Far-Western assay as described in Experimental Procedures (upper panel). The membrane was stripped and probed with an anti-pRB
antibody (lower panel).
D: Whole-cell lysate from HEK293 cells transfected with a plasmid expressing HA-HMGA2 (5 mg) was subjected to GST pull-down analysis using the GST or GST-
pRB fusion proteins reported in (B). Binding reaction products were washed, and proteins were separated by SDS-PAGE. The membrane was probed with both
anti-HA and GST antibodies.
E: Schematic representation of plasmids expressing wild-type and mutant HA-HMGA2 proteins used for the analysis.
F: Whole-cell lysates from HEK293 cells transfected with the plasmids reported in (E) were subjected to GST pull-down analysis using GST-pRB protein beads
(upper panel) or GST protein beads (medium panel) as control. Aliquots of the same lysates were probed with anti-HA antibody to evaluate the comparable
expression of the transfected plasmids (lower panel).462 CANCER CELL JUNE 2006
A R T I C L EFigure 3. HMGA2 counteracts the pRB-mediated inhibition of E2F activity and cell proliferation
A: Luciferase activities of extracts from HEK293 cells cotransfected with CDC25A-luc or CDC6-luc reporter plasmids and increasing amounts of HMGA2 with or
without a pRB expression vector. The RSV-luc plasmid served as a negative control. Relative activities were calculated by dividing normalized activities with
the activity of cells transfected with the reporter plasmid alone. Aliquots of the same lysates were resolved by SDS-PAGE, transferred to Immobilion-P, and
immunoblotted with the indicate antibodies (lower panels).
B: Saos-2 cells were transiently transfected with plasmids expressing HA-HMGA2 wild-type and mutated proteins and subjected to luciferase assay on the
CDC6-luc reporter promoter. Relative activities were calculated as reported in (A). Aliquots of the same lysates were resolved by SDS-PAGE and immunoblot-
ted with the indicate antibodies (lower panels).
C: Saos-2 cells were transiently transfected with the expression plasmids indicated on the left and selected for 14 days in the appropriate antibiotic. Cell clones
were counted following staining with crystal violet.
D: Focusassay on Rat-2 cells transfected with the plasmids indicated on the left. The transforming efficiency was expressed as foci-forming units (f.f.u.)/pmol of
transfected DNA. All the data reported are the mean 6 SE of three independent experiments. *p < 0.05; **p < 0.01.pRB greatly reduced the colony-forming ability. Cell growth in-
hibition was significantly reduced in the presence of a coex-
pressed HMGA2 construct and was not affected by either the
A2(1-44) or A2(D45-56) mutant. Conversely, HMGA2 alone had
no significant effects on colony-forming ability. These results
suggest that HMGA2, by interacting with pRB, inhibits the
pRB negative regulation of E2F1 activity, thereby blocking its
growth-suppressing potential.
The binding of HMGA2 to pRB is crucial
for its transforming activity
It has been previously reported that HMGA2 induces neoplastic
transformation of cultured rat fibroblasts (Wood et al., 2000),
demonstrating its oncogenic potential. In order to verify whether
the binding between HMGA2 and pRB, with the resulting pRB
inactivation, might be responsible for the oncogenic properties
of HMGA2, we evaluated the focus-forming ability of HMGA2
and pRB binding mutants of HMGA2. To do this, we transfectedCANCER CELL JUNE 2006Rat-2 cells with either HMGA2 or each of the HMGA2 mutants
unable to efficiently bind to pRB. As shown in Figure 3D, the
wild-type HMGA2 was able to induce foci, whereas no foci
were observed in transfected cells with both the HMGA2 mu-
tants. High transforming efficiency was obtained by transfecting
the activated Ha-Ras gene (Ras 12V) that we used as a positive
control of the assay. These results suggest that the binding be-
tween HMGA2 and pRB is necessary for the HMGA2 oncoge-
nicity and that the mechanism by which HMGA2 is involved in
pituitary tumorigenesis may be generally involved in HMGA2-
mediated cell transformation.
HMGA2 displaces HDAC1 from the pRB/E2F complex
Many cellular and viral proteins have been shown to bind pRB
within the pocket region of pRB (Hu et al., 1990). Consequent
to this process, E2F1 is released from the binding to pRB and
becomes active. Because HMGA2 binds to pRB in this same
pocket region, we tested the hypothesis that the HMGA2/pRB463
A R T I C L EFigure 4. HMGA2 competes with HDAC1 but not
with E2F1 for pRb binding
A: HEK293 cell lysates coexpressing both E2F1
and pRB transiently transfected plasmids were
subjected to immunoprecipitation with anti-
pRB antibody after incubation with either
HMGA2 or E1A recombinant proteins, as indi-
cated above, and then blotted against either
E2F1 or HDAC1, as indicated on the left. pRB
Western blot served as a control of the equal
loading of the immunoprecipitated pRB protein.
B: Labeled HDAC1 and recombinant pRB were
coimmunoprecipitated with or without 5 or 10
mg of either recombinant HMGA2 or A2(1-44)
proteins. The samples were then blotted and
probed with either HDAC1 or pRB antibody, as in-
dicated on the left.
C: Lysates from Saos-2 cells, transiently trans-
fected with the plasmids indicated on the left
or with the empty vector, were incubated with
a recombinant pRB protein and immunoprecip-
itated with anti-pRB antibodies. The resulted im-
munoprecipitates were in part subjected to his-
tone deacetylase assay as described under
Experimental Procedures and in part run on
a SDS-PAGE for evaluation of the equal amount
of pRB immunoprecitated in each sample.
D: Lysates from a pool of pituitary glands of wild-
type mice and one pituitary adenoma of
HMGA2 transgenic mice were assayed as in
(C). The results reported in (C) and (D) are the
mean 6 SE of three independent experiments.
*p < 0.05; **p < 0.01.
E: Cell inputs from the experiments shown in (C)
and (D) were assayed by Western blot for the ex-
pression of the HDAC1 protein.interaction interferes with the binding between pRB and E2F1,
thereby inducing E2F1 activation. To this aim, we performed
coimmunoprecipitation experiments with HEK293 cells tran-
siently cotransfected with pRB and E2F1 expression plasmids
in the presence of E1A or HMGA2 recombinant proteins
(Figure 4A). As previously reported (Putzer et al., 1997), E1A pre-
vented the binding between pRB and E2F1 (lane 2), whereas
HMGA2 did not (lane 3). Thus, HMGA2 does not activate E2F1
by competing with it for binding to pRB.
Another mechanism by which the pRB/E2F complex re-
presses transcription entails recruitment of a histone deacety-
lase, the HDAC1 protein, to the E2F binding sites by pRB (Mag-
naghi-Jaulin et al., 1998). Histone acetyl transferases and
histone deacetylases acetylate and deacetylate, respectively,
core histone tails that protrude from the nucleosome. Histone
acetylation is thought toweaken the interaction between histone
N-terminal tails and DNA, thus opening up the chromatin and in-
creasing accessibility for activating transcription factors. There-
fore, the binding of the viral transforming proteins to the pRB-
pocket region results in the loss of E2F and HDAC1 binding.
We thus asked whether the HMGA2/pRB interaction could
displace HDAC1 from the pRB/E2F complex, and so account
for E2F1 activation. To this aim, we used the same immunopre-
cipitates described above to also analyze the binding of HDAC1
to pRB. As shown in Figure 4A, both E1A (lane 2) and HMGA2
(lane 3) reduced the binding of pRB to HDAC1. This shows
that, similarly to the E1A/pRB interaction, the HMGA2/pRB
complex can affect HDAC1 recruitment.464To verify this result, we used a cell-free system in which
pRB and HDAC1 recombinant proteins were incubated with or
without increasing amounts of a recombinant HMGA2 protein.
As shown in Figure 4B, HDAC1 was partially or completely dis-
placed by the binding to pRB in the presence of 5 mg and 10 mg
of HMGA2, respectively. This result demonstrates that HMGA2
directly interferes with the binding between HDAC1 and pRB.
Moreover, to correlate the effect of HMGA2 onHDAC1 displace-
ment from pRB with the HMGA2/pRB interaction, we also per-
formed the experiment by using the A2(1-44) mutant, unable
to bind pRB. As shown in the same Figure 4B, the binding be-
tween HDAC1 and pRB was not affected at all by the HMGA2
mutant, suggesting that the interaction between HMGA2 and
pRBplays a crucial role in the displacement ofHDAC1 frompRB.
Because recruitment of HDAC1 by pRB to gene promoters
decreases their level of histone acetylation (Magnaghi-Jaulin
et al., 1998), we evaluated whether HMGA2 overexpression
was associated with decreased HDAC activity associated with
the pRB complexes. To this aim, lysates from Saos-2 cells, tran-
siently transfected with either HMGA2 or each of the two
mutants A2(1-44) and A2(D45-56), were incubated with a re-
combinant pRB protein and then immunoprecipitated with anti-
bodies against pRB. These immunoprecipitates were incubated
with a 3H-acetylated histone H4 peptide, and the released 3H-
acetate was measured (Figure 4C). The same assay was carried
out with mouse tissue lysates from wild-type pituitaries and
HMGA2 transgenic pituitary adenomas (Figure 4D). Consistent
with the HMGA2-induced displacement of HDAC1 from theCANCER CELL JUNE 2006
A R T I C L EFigure 5. HMGA2 displaces HDAC1 from E2F1 target promoters
A: Lysates from cells transfected with plasmids expressing pRB, E2F1, and HMGA2 or pRb, E2F1, and empty vector, as indicated above the panel, were sub-
jected to ChIP using specific polyclonal antibody, as indicated on the right. Before reversal of formaldehyde cross-linking, each precipitate was washed, re-
suspended, and subjected to re-ChIP using specific antibody as indicated on the top. Immunoprecipitates from each sample were analyzed by PCR, and
a sample representing linear amplification (0.25–1 ml) of the total input chromatin (Input) was included in the PCRs as a control.
B: Increasing amounts of input samples as described in (A) were used as template in PCR amplifications performed using primers specific for the different pro-
moters including E2F binding sites: CDC2, TK1, and cyclin E1.
C: Lysates from cells transiently transfected as described in (A) and indicated above the panel were subjected to Western blot analysis with anti-pRB, anti-Ha
(for HMGA2), or anti-E2F1 antibodies to verify protein expression. Tubulin expression served as a control of equal protein loading.
D: Tissue extracts from a pool of normal pituitary glands (PG) and a representative HMGA2-induced pituitary adenoma (PA) were assayed by ChIP using a spe-
cific polyclonal antibody anti-HDAC1. Immunoprecipitates from each sample were analyzed by PCR, and a sample representing linear amplification (0.25–
1 ml) of the Input was included in the PCRs as a control. Another control included precipitation performed without specific IgG.
E: Increasing amounts of input samples as described in (D) were used as template in PCR amplifications carried out with primers specific for the different pro-
moters: CDC2, TK1, and Gapdh.pRB active repressor complex, HDAC activity was significantly
lower in cells and pituitary adenomas overexpressing HMGA2
than in mock-transfected cells and normal pituitary, respec-
tively. To exclude that this effect could be due to a downregula-
tion of HDAC1 expression following HMGA2 overexpression, we
also monitored HDAC1 expression in the inputs of the experi-
ments shown in Figures 4C and 4D. As shown in Figure 4E, no
differences in HDAC1 expression were observed between
HMGA2-transfected and parental cells or between pituitary ad-
enoma and normal gland.
HMGA2 binds to E2F target promoters in vivo
and interferes with the association of the single
subcomplexes
We next evaluated whether HMGA2 is part of the complexes, in-
cluding pRB, E2F1, and HDAC1 that form at the E2F bindingCANCER CELL JUNE 2006sites of the E2F-responsive promoters in vivo, and whether it
can displace HDAC1. In a combination of chromatin immuno-
precipitation (ChIP) and Re-ChIP analyses, HEK293 cells were
transfected with pRB and E2F1 or pRB and E2F1 plus HMGA2
(Figure 5C), and crosslinked genomic DNA was immunoprecip-
itated in two rounds with two specific antibodies directed
against protein components of the complex (Figure 5A). Re-
ChIPed DNA was analyzed by PCR using promoter-specific
primers that encompass the E2F binding sites, under conditions
of linear amplification (Figure 5B). Figure 5A shows that HMGA2
can associate in vivo with three E2F-responsive promoters, i.e.,
those driving CDC2, TK1, and cyclin E1 gene transcription, and
is a component of a promoter-bound multimeric complex con-
taining E2F1, pRB, and HDAC1. A comparison of the subcom-
plexes with and without HMGA2 revealed three mechanisms
whereby HMGA2 can activate E2F1 in vivo. First, in agreement465
A R T I C L Ewith our in vitro results, HDAC1/pRB binding was decreased in
the presence of HMGA2 on all the promoters analyzed, espe-
cially the TK1 promoter. Second, pRB/E2F binding is decreased
in the presence of HMGA2 on the cyclin E1 promoter, suggest-
ing that HMGA2 can displace pRB from E2F1, at least on this
promoter. Finally, E2F1 binding on the TK1 promoter was signif-
icantly increased in the presence of HMGA2, suggesting that, at
least on this promoter, HMGA2 can directly enhance the binding
of free E2F1 to the DNA target. This effect was also observed in
the EMSA with an E2F consensus oligonucleotide (Figure 1).
Quantitative data of this experiment, evaluated by densitometric
analyses, are shown in the Figure S1 in the Supplemental Data
available online.
To improve the significance of the HMGA2-mediated dis-
placement of HDAC1 from the E2F-responsive promoters, we
performed ChIP analyses on tissue extracts from normal and
neoplastic pituitary tissues from wild-type and transgenic
mice, respectively, using specific anti-HDAC1 antibodies. The
DNA that was immunoprecipitated was analyzed by PCR using
promoter-specific primers that encompass the E2F binding
sites under conditions of linear amplification (Figure 5E). As
shown in Figure 5D, differently from what occurs in normal pitu-
itary glands from control mice, the binding of HDAC1 to the pro-
tein complex bound to the E2F-responsive promoters is much
more reduced compared to normal tissue.
Overexpression of HMGA2 promotes acetylation
of histones and E2F1 protein on E2F target promoters
in vivo
We have shown that HMGA2 can displace HDAC1 from pRB at
the E2F binding sites—a process that could account for the de-
creasedHDAC activity associatedwith HMGA2 overexpression.
HDAC can also affect proteins that can be acetylated. An exam-
ple of this is E2F1, whose acetylation augments DNA binding
and stabilizes the protein (Martinez-Balbas et al., 2000).
To analyze the acetylation status of histones and E2F1 on
E2F1 target promoters in vivo, we transfected Saos-2 cells
with pRB or pRB and HMGA2 (Figure 6A) and subjected the ly-
sates to a ChIP assay using specific anti-acetylated histone H3
antibodies (Figure 6B). Immunoprecipitated DNA was analyzed
by PCR using promoter-specific primers that encompass the
E2F binding sites under conditions of linear amplification
(Figure 6C). Control vector-transfected cells had high levels of
acetylated histone H3 in association with the E2F binding sites
of the analyzed promoters (Figure 6B). Overexpression of pRB
decreased the association of the acetylated histone H3 with
the same promoters, but not with the glyceraldehyde-3-phos-
phate dehydrogenase (Gapdh) unrelated promoter. In contrast,
coexpression of pRB and HMGA2 abolished the effects of pRB.
In order to investigate E2F1 acetylation on the same promoters
and correlate it with the HMGA2/pRB interaction, we trans-
fected HEK293 cells with either HMGA2 or A2(1-44) and sub-
jected the lysates to a ChIP assay with a specific anti-acetylated
E2F1 antibody. As shown in Figure 6D, E2F1 acetylation was en-
hanced by the HMGA2 overexpression, whereas it did not
change in cells transfected with the A2(1-44) mutant. This result,
consistent with our previous data demonstrating the role of the
HMGA2/pRB interaction in displacing HDAC1 from the E2F-re-
sponsive promoters, was also confirmed by an additional exper-
iment in which total lysates from cells transfected as in Figure 6D466were immunoprecipitated with the anti-acetylated E2F1 anti-
body and then blotted for E2F1 (Figure 6F).
Finally, to evaluate whether these results correspond to real
regulation of the expression of these genes in vivo, we carried
out a semiquantitative reverse transcriptase-PCR. The expres-
sion levels of CDC2 and TK1 mRNA were measured in Saos-2
cells upon overexpression of pRB or pRB andHMGA2. In agree-
ment with the results reported above, these genes were specif-
ically downregulated upon pRB expression, but not upon coex-
pression of pRB and HMGA2 (Figure 6G).
Loss of E2F1 suppresses the development of pituitary
tumors in HMGA2 transgenic mice
The afore-reported data demonstrate that HMGA2 induces
E2F1 activity in pituitary adenomas by enhancing E2F1 acetyla-
tion and the binding of free E2F to the target promoter. This sug-
gests that E2F1 activity is a critical event in pituitary tumorigen-
esis of HMGA2 mice.
To address this hypothesis, we crossed HMGA2 transgenic
mice (HMGA2TG) withE2f12/2mice to generate doublemutants.
We obtained HMGA2TG;E2f1+/2 and HMGA2TG;E2f12/2 in
a mixed 129/Sv3 C57BL/6 genetic background. We monitored
the female double mutants for the development of pituitary tu-
mors, using HMGA2TG;E2f1+/+ female mice as controls. All con-
trol animals (9/9) and nearly allHMGA2TG;E2f1+/2 (13/14) double
mutants developed grossly detectable pituitary tumors by the
age of 15 months (see arrow in Figure 7A). In contrast, only 4
of the 16 (25%) HMGA2TG;E2f12/2mice developed pituitary tu-
mors (Figures 7A and 7B) at the same age. The loss of E2F1
function significantly affected the penetrance of pituitary tumors
in HMGA2TG mice (p = 0.0121; log rank test). In addition, the tu-
mors in the HMGA2TG;E2f1+/+mice featured multiple neoplastic
nodules constituted by cords and solid nests of monomorphous
polygonal tumor that had a high mitotic activity and intense
PCNA labeling (Figures 7Cd and 7Ce); the nodules enlarged,
distorted or completely replaced the anterior pituitary lobe. In
contrast, the pituitary adenomas in the HMGA2TG;E2f12/2 ani-
mals were neither grossly enlarged nor distorted, and the ante-
rior lobe showed a normal acinar pattern, except for a small nod-
ule containing a few blood-filled spaces and rare mitotic figures
and PCNA labeling (Figures 7Cj and 7Ck). The Gordon-Sweet
silver method was used for the histological diagnosis of these
nodules (Figure 7Cl) and showed focal disruption of the reticulin
fiber network, which is pathognomic for the adenomatous trans-
formation of pituitary cells (Figures 7Cc and 7Cf). These results
provide strong evidence that E2F1 activation is required for
the development of pituitary adenomas in HMGA2 transgenic
mice.
In order to further investigate the molecular mechanisms in-
volved in the pituitary alterations of the few cases of HMGA2TG;
E2F12/2 mice that develop small adenomas, we analyzed the
status of pRB/HMGA2 complexes and E2F ‘‘free’’ activation in
these E2F1 null tumors. As shown in Figure 7D, HMGA2 and
pRB still retain their capacity to interact with each other. How-
ever, the E2F ‘‘free’’ DNA binding activity does not show any sig-
nificant increase in these tumors compared to control wild-type
pituitary glands (Figure 7E, lane 3). Conversely, a strong in-
crease in E2F free DNA binding was always observed in pituitar-
ies from HMGA2TG;E2f1+/+ mice even before the appearance of
the pituitary tumor (Figure 7E, lane 2). Thus, even though
HMGA2 is still able to bind pRB in absence of E2F1, there areCANCER CELL JUNE 2006
A R T I C L EFigure 6. HMGA2 overexpression increases acetylation of both histones and E2F1 protein on E2F target promoters
A: Western blot analysis showing the protein expression of pRB and HMGA2 in Saos-2 cells transiently transfected with the relative expression plasmids, as in-
dicated on the top. Tubulin expression served as a control of equal protein loading.
B and C: Lysates from Saos-2 cells transfected as described in (A) were subjected to ChIP using specific polyclonal antibodies anti-acetylated histone H3 (B).
Immunoprecipitates were analyzed by PCR, and a sample representing linear amplification (0.25–1 ml) of the Input was included in the PCRs as a control. An-
other control included precipitation performed without specific IgG. Increasing amounts of input samples (C) were used as template to verify the linear range
of amplification.
D: HEK293 cells transfected with E2F1, HMGA2, A2(1-44), or the backbone vector alone were assayed by ChIP using a specific polyclonal antibody anti-acet-
ylated E2F1 under the same conditions as described in (B).
E: Increasing amount of input samples from the experiment described in (D) were used as template to verify the linear range of amplification.
F: HEK293 cells transfected as described in (D) were immunoprecipitated with anti-acetylated E2F1 antibody and assayed by Western blot for E2F1 (upper
panel). The inputs were assayed by Western blot for the expression of endogenous pRB and transfected HMGA2 and A2(1-44) proteins (middle and lower
panels).
G: RNA from Saos-2 cells transiently transfected as described in (A) was analyzed by RT-PCR for the expression of CDC2, TK1, and Gapdh. The RT control lanes
represent RT-PCR without reverse transcription.no alternative E2F proteins whose DNA binding activity is en-
hanced following this interaction, suggesting that other E2F-in-
dependent mechanisms may be responsible for the pituitary
alterations in the minority of these mice.
Discussion
Tumors of the pituitary gland can be found in 20% of the popu-
lation, and at least one-third of these cause health complica-
tions. In fact, although not classified asmalignant, most pituitary
adenomas grow rapidly and can invade downward into the para-
nasal sinuses, laterally into the cavernous sinuses, and upward
into the parenchyma of the brain. Little is known about the mo-
lecular events responsible for pituitary transformation (reviewedCANCER CELL JUNE 2006by Asa and Ezzat, 2002). A large body of evidence implicates
HMGA2 in pituitary tumorigenesis (Fedele et al., 2002; Finelli
et al., 2002). In an attempt to identify the mechanism by which
HMGA2 acts, we explored the pRB pathway. We selected this
strategy because of experimental data indicating that the
HMGA2 gene interferes with this pathway (Bignon et al., 1993;
Fedele et al., 2002; Jacks et al., 1992). Moreover, the finding
that mice with heterozygous RB mutations develop pituitary tu-
mors (Jacks et al., 1992) suggests that impairment of the pRB/
E2F pathway is involved in pituitary tumorigenesis. Thus far,
RBmutations have not been identified in human pituitary adeno-
mas (Cryns et al., 1993). However, methylation of the RB gene-
promoter region at a CpG island in human pituitary tumor cells
resulted in loss of protein expression (Simpson et al., 2000),467
A R T I C L EFigure 7. The absence of E2F1 suppresses pituitary tumorigenesis in HMGA2 transgenic mice
A: MRI analysis of a representative 12-month-old transgenic mouse homozygous for the knockout mutation of E2F1 (right: HMGA2TG;E2f12/2), com-
pared with a sex-age matched control transgenic mouse (left: HMGA2TG; E2f1+/+). The arrow indicates the pituitary tumor that is absent in the E2f12/2
mouse.
B:HMGA2 transgenic mice and E2f12/2mice were crossed to generateHMGA2TG;E2f1+/+,HMGA2TG;E2f1+/2, andHMGA2TG;E2f12/2mice. The total number of
pituitary tumors developed by each genotype is shown.
C: Histological analysis (hematoxylin and eosin staining) of the anterior pituitary from a wild-type animal showing a normal architecture (Ca), absence of
PCNA labeling (Cb), and a normal acinar pattern and reticulin network (Gordon-Sweet silver stain) (Cc). HMGA2TG;E2f1+/+ mice had a very large tumor
that enlarged and completely replaced the anterior lobe (Cd); most neoplastic cells showed PCNA labeling (Ce), and the reticulin network was lost (Cf).
HMGA2TG;E2f12/2 mice showing either a morphology (Cg), PCNA labeling (Ch), and reticulin network (Ci) similar to wild-type mice, or neoplastic nodules468 CANCER CELL JUNE 2006
A R T I C L Ewhich confirms that pRB is important in human pituitary tumor-
igenesis.
By repressing E2F1 activity, the pRB protein prevents cells
from progressing beyond the G1 phase of the cell cycle. Phos-
phorylation of pRB by cyclin-cdk complexes or expression of vi-
ral transforming proteins relieves this repression and allows cells
to progress toward S phase (reviewed by Seville et al., 2005). In-
teraction of pRB with histone deacetylase HDAC1 is involved in
pRB repression of E2F1 activity, and this interaction is disrupted
by both phosphorylation and viral transforming proteins (Mag-
naghi-Jaulin et al., 1998).
Here we demonstrate that HMGA2 induces the development
of pituitary adenomas by enhancing E2F1 activity. In fact, E2F1
activity was drastically increased in all pituitary tumors analyzed.
Moreover, the absence of E2F1, obtained by mating HMGA2
transgenic with E2f1 knockout mice, greatly inhibited the forma-
tion of pituitary tumors. In fact, most HMGA2TG;E2f12/2 mice
did not develop tumors, and only a few had small, slow grow-
ing adenomas. The reduced severity of pituitary lesions in
HMGA2TG;E2f12/2 animals suggests that loss of E2F1 may de-
lay the onset or progression of these tumors. It is noteworthy
that the loss of one wild-type E2F1 allele did not alter the fre-
quency of pituitary tumors in HMGA2TG mice.
Themechanismbywhich the HMGA2protein affects the pRB/
E2F pathway and enhances E2F1 activity is quite unique. In fact,
although HMGA2 binds to the pRB pocket, it does not compete
with the E2F protein in pRB binding, unlike proteins encoded by
the adenovirus E1A gene. Conversely, our data show that
HMGA2 activates E2F by interfering with HDAC1 recruitment
by pRB on various E2F-responsive promoters (Figure 8). Dis-
placement of HDAC1 would result in acetylation of both
E2F1 and DNA-associated histones, thereby promoting E2F1
activation.
It would be worthwhile to investigate whether HMGA2 is able
to displace also the other HDAC members (as suggested by our
preliminary experiments) and any other protein associated to the
pRB/E2F complex.
HDAC1 displacement from pRB is not the only way by which
HMGA2 activates E2F1. HMGA2 also acts directly on the E2F-
responsive DNA elements, and at least on the TK1 promoter
causes enhanced E2F1 DNA binding (Figure 5A). Although we
do not demonstrate in vitro that HMGA2/pRB binding caused
displacement of E2F1 from pRB, we show that HMGA2, at least
on the cyclin E1 promoter, displaced pRB from the E2F1-DNA
complex (Figure 5A). On the basis of our results it is reasonable
to suppose that displacement of pRB from E2F1 does not occur
simply through competition between E2F1 and HMGA2 for the
A/B pocket of pRB, but through a more indirect mechanism
due to the enhanced E2F1 acetylation dependent upon the
HMGA2 overexpression. In fact, it has been proposed (Marti-
nez-Balbas et al., 2000) that acetylation stimulates the functions
of the non-RBbound ‘‘free’’ form of E2F1, including DNAbinding
and its protein stability.
In conclusion, HMGA2 induces pituitary adenomas by en-
hancing E2F1 activity through displacement of HDAC1 fromCANCER CELL JUNE 2006pRB and consequent induction of E2F1 acetylation. It is likely
that the same mechanism may be involved in most human pro-
lactinomas in which the HMGA2 gene is amplified and overex-
pressed. Should this be the case, onemay envisage a therapeu-
tic strategy aimed at disrupting this mechanism.
Experimental procedures
Electrophoretic mobility shift assay
Protein/DNA binding was determined by electrophoretic mobility shift assay
(EMSA), as previously described (Battista et al., 2005). The E2F1 oligonucle-
otide (Santa Cruz, CA; sc-2507) was mutated as follows (mutated bases in
bold) in the AT-mut oligonucleotide: 50-ACTTGGGTTTCGCGC
CCTTTCTCAA-30. The antibodies used were anti-HMGA2 (polyclonal Ab
raised against a synthetic peptide located in the NH2-terminal region) and
anti-E2F1 (sc-193, Santa-Cruz). The DNA-protein complexes were resolved
on 6% (w/v) nondenaturing acrylamide gels and visualized by exposure to
autoradiographic films. Binding reactions with the purified proteins were car-
ried out as previously described (Baldassarre et al., 2001).
Protein extraction, immunoblot analysis, and immunoprecipitation
Tissues were rapidly dissected, frozen on dry ice, and stored at280ºC. Pro-
tein extraction, Western blot, and immunoprecipitation were carried out as
previously described (Pierantoni et al., 2001). The antibodies used were
anti-HMGA2 (polyclonal antibody raised against a synthetic peptide located
in the NH2-terminal region), anti-pRB (C-15, Santa Cruz, CA), anti-HA (F-7;
Santa Cruz), anti-GST (B-14, Santa Cruz), anti-E2F1 (C-20, Santa Cruz),
and anti-HDAC1 (06-720, Upstate Biotechnology Inc., Lake Placid, NY).
Plasmids and recombinant proteins
HA-tagged HMGA2 expression plasmids containing the entire and various
separate portions of the HMGA2 coding sequence were obtained by PCR
amplification and subcloned into the pCEFL-HA expression vector. The ex-
pression vectors for pRB and all pRB mutants (each subcloned into the
CMV-neo-Bam vector) were kindly donated by G. Condorelli. CDC25A-luc
and CDC6-luc plasmids were already described (Hateboer et al., 1998;
Vigo et al., 1999). pRB(379-928), pRB(1-379), pRB(379-928)D21, pRB(379-
792), pRB(768-928), pRB(834-928), and E2F1 were expressed as GST fusion
proteins, whereas HMGA2 and E1A-12S were expressed as His fusion pro-
teins. pGEX2T plasmids carrying the different deletion mutants of pRB
were kindly provided by S. Soddu. The pCMVHAE2F1 and pGST20TE2F-1
vectors are described elsewhere (Helin et al., 1993; Helin and Harlow,
1994). The GST and His fusion proteins were expressed in Escherichia coli
strain BL21 (DE3) (Stratagene) and purified using glutathione sepharose or
nickel beads as previously described (Baldassarre et al., 2001; Pierantoni
et al., 2001). The pRB full-length recombinant protein was from Abcam (ab
1111).
Pull-down and Far-Western experiments
Pull-down analysis was carried out as previously described (Pierantoni et al.,
2001). For Far-Western analysis, 50 mg of cell lysates expressing pRBand dif-
ferent pRBmutants were separated by SDS PAGE and transferred to a nitro-
cellulosemembrane. Themembranewas air-dried, and the proteins were de-
naturated for 10 min in 6 M guanidine hydrochloride in HBB buffer (10 mM
HEPES, pH 7.5, 60 mM KCl, 1 mM EDTA, and 1 mM DTT). The proteins
were renaturated sequentially in 3, 1.5, 0.75, 0.38, and 0.19 M GuHCl in
the same buffer (10 min each step). The membrane was extensively rinsed
with HBB and blocked with HBB supplemented with 5% nonfat milk and
0.5% NP40 for 1 hr at 4ºC and for 30 min in HBB with 1% milk. The His-
HMGA2 protein was incubated with the membrane in PIB buffer (10 mM
HEPES, pH 7.5, 13 mM NaCl, 50 mM KCl, 1% milk, and 0.5% NP40, 1 mM
DTT) for 4 hr at 4ºC. The unbound material was removed with extensivethat differed from those in HMGA2TG;E2f1+/+ mice in that they were smaller (Cj), had less intense PCNA labeling (Ck), and only partial loss of the reticulin net-
work (Cl). Scale bars (in yellow): 100 mm H&E, 75 mm PCNA staining, 25 mm Gordon-Sweet silver stain.
D: Coimmunoprecipitation of HMGA2 and pRB in tissue extracts from pituitary glands and tumors from mice as indicated on the top.
E: EMSA analysis of wild-type (WT), HMGA2TG;E2f1+/+ (TG +/+), and HMGA2TG;E2f12/2 (TG2/2) pituitary samples, either normal (N) or adenomatous (PA), using
a consensus E2F as probe.469
A R T I C L Ewashes for 30 min in the same buffer. Binding was detected with Western
blot analysis and anti-His antibody (Santa Cruz).
Cell lines and transfections
The HEK293, Rat-2, and Saos-2 cell lines were grown in Dulbecco’smodified
Eagle medium (DMEM) (Gibco-BRL) supplemented with 10% fetal-calf se-
rum (Gibco-BRL). HEK293 cells were transfected by calcium phosphate pre-
cipitation by standard procedures. Rat-2 and Saos-2 cells were transfected
by lipofectamine-plus reagent (Invitrogen) according to the manufacturer’s
instructions. For the luciferase activity assay, cells were transfected with
0.2 mg of CDC25A-luc or CDC6-luc reporter plasmids with or without 0.2 mg
of pRB expression vector and increasing amounts (1 mg, 5 mg, and 10 mg)
of HA-HMGA2 expression vector or 1 mg of HA-A2(1-44) or HA-A2(D45-56)
plasmid. One microgram of pCMVbgal plasmid was cotransfected to verify
equal transfection efficiency in the cell lines tested. Cells were harvested
36 hr after transfection, and luciferase and b-galactosidase activities were
measured with a luminometer (Lumat LB9507, Berthold) with the Dual light
Figure 8. Model of E2F1 activation by HMGA2
Following HMGA2 overexpression, transcription through E2F1 sites switches
from repression to activation throughout four steps.
A: HMGA2 binds to pRB, which is complexed with E2F1 and HDAC1 to form
the active repression.
B: The interaction between HMGA2 and pRB displaces HDAC1.
C: In the absence of HDAC1, the histone acetylase enzymes are recruited
and, by acetylating histones, relieve transcriptional repression.
D: Histone acetylases also acetylate E2F1 causing the stabilization of its
‘‘free’’ active form.470kit (Tropix). The data represent the average of three independent experi-
ments, performed in duplicate, with standard errors. Colony and Focus as-
says were carried out as previously described (Pierantoni et al., 2001; Fedele
et al., 1998).
Competition experiments
Whole-cell lysates from HEK293 cells transiently cotransfected with HA-
E2F1 and pCMV-pRB were incubated for 1 hr with His-HMGA2 or His-E1A
recombinant proteins and subjected to immunoprecipitation with anti-pRB
antibody (C-15, Santa Cruz, CA), resolved by SDS-PAGE on a 12% gel,
and analyzed by Western blot with anti-E2F1 (C-20, Santa-Cruz), anti-
HDAC1 (06-720, Upstate Biotechnology), or anti-pRB antibodies (C-15,
Santa Cruz). In another experiment, labeled HDAC1 and a recombinant
GST protein were subjected to immunoprecipitation with or without 5 or
10 mg of recombinant His-HMGA2 or His-A2(1-44). The samples were re-
solved by 12% SDS-PAGE gel and probed with anti-pRB antybody (C-15,
Santa Cruz).
Deacetylase assay
Deacetylase assays were carried out with a histone deacetylase assay kit
(Upstate Biotechnology) according to the manufacturer’s instructions. All
experiments were carried out three times, and samples were assayed in
duplicate.
Chromatin immunoprecipitation and reprecipitation
Chromatin immunoprecipitation (ChIP) was carried out with an acetyl-histone
H3 immunoprecipitation assay kit (Upstate Biotechnology) according to the
manufacturer’s instruction. For ChIp experiments with the polyclonal anti-
body anti-HDAC1 (Upstate Biotechnology), anti-E2F1 (C-20 Santa Cruz),
anti-pRB (C-15 Santa Cruz), and anti-HMGA2 (polyclonal antibody raised
against a synthetic peptide located in the NH2-terminal region), conditions
were as previously reported (Shang et al., 2000). For Re-ChIP experiments,
complexes were eluted by incubation for 30 min at 37ºC in 250 ml of Re-
ChIP elution buffer (2 mM DTT, 1% Triton X-100, 2 mM EDTA, 150 mM
NaCl, 20 mM Tris-HCl, pH 8.1) and then diluted 4-fold in Re-ChIP dilution
buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH
8.1) and subject again to the ChIP procedure. Crosslinking was reversed
by incubating samples overnight at 65ºC with 20 ml of 5 M NaCl. Samples
were then incubated in proteinase K solution (10 mM EDTA, 40 mM Tris-
HCl, pH 6.5, 40 mg/ml of Proteinase K) for 1 hr at 45ºC. DNA was purified
with phenol/chloroform/isoamyl alcohol and precipitated by adding 2 vol-
umes of ethanol and tRNA. PCR reactions were carried out by standard pro-
cedures, for a number of cycles optimized to ensure product intensity within
the linear phase of amplification. The PCR products were separated on a 2%
agarose gel, stained with ethidium bromide, and either scanned using a Ty-
phoon 9200 scanner or blotted and hybridized with specific probes. Primer
sequences are available as Supplemental Data.
Reverse transcriptase-PCR
Total RNA was isolated using TRI-reagent solution (Sigma) according to the
manufacturer’s protocol and treated with DNase (Invitrogen). Reverse tran-
scription was performed by standard procedures. Primer sequences are
available as Supplemental Data.
Generation and genotyping of mutant mice
E2f1-deficient animals ofmixed 129/SvxC57BL/6 genetic background (Jack-
son Laboratory) were mated to HMGA2 transgenic (HMGA2TG) animals
(Fedele et al., 2002) to generate HMGA2TG;E2f1+/2 mice. Subsequent inter-
matingofHMGA2TG;E2f1+/2malesand femalesproducedHMGA2TG;E2f12/2
mice. Animals were genotyped from tail DNA using Southern blot and PCR as
previously described (Fedele et al., 2002) and according to the Jackson pro-
tocol. Mice were maintained under specific pathogen-free conditions in our
Laboratory Animal Facility (Istituto dei Tumori di Napoli, Naples, Italy), and
all studies were conducted in accordance with Italian regulations for
experimentations on animals.
Histological analyses
Paraffin-embedded sections 4–5 mm thickwere stainedwith hematoxylin and
eosin and with the Gordon-Sweet silver method for the reticulin matrix. Im-
munohistochemical staining to identify proliferating cells was carried outCANCER CELL JUNE 2006
A R T I C L Ewith the PCNA antibody (Novocastra) and the streptavidin-biotin peroxidase
technique (DAKO Corp., CA).
Magnetic resonance
Magnetic resonance imaging was carried out at the Istituto dei Tumori di Na-
poli G. Pascale with a 1.5-T magnet system using local receiver coils and an
8 cm field of view. Sagittal slices 3 mm thick were obtained with T1 weighting
(TR/TE = 400/11 ms).
Supplemental Data
The Supplemental data for this article can be found online at http://www.
cancercell.org/cgi/content/full/9/6/459/DC1/.
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